Published in:
Open Access 01-01-2016 | Special Article
Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006
Published in: Breast Cancer | Issue 1/2016
Login to get accessExcerpt
The prognostic study for the Japanese Breast Cancer Society (JBCS) registry in 2006 was finally published here (Figs. 1, 2, 3, 4, 5, 6, 7, 8, 9, Sup. Table 1–9). The JBCS registry has been started from 1975. To 2003, for 29 years, 188,265 cases have been registered. With the cooperation of the Non-Profit Organization Japan Clinical Research Support Unit (J-CRSU) and the Public Health Research Foundation, we have moved to the new system by the web registration from 2004.
Fig. 1
a, b Kaplan–Meier curves for relapse-free and overall survival of all cases by tumor classification (cT-category). P values were calculated using the log rank test. Tis non-invasive ductal carcinoma, lobular carcinoma in situ, or Paget disease, T1a ≤0.5 cm, T1b 0.5 < tumor ≤ 1.0 cm, T1c 1.0 < tumor ≤ 2.0 cm, T2 2.0 < tumor ≤ 5.0 cm, T3 >5.0 cm, T4 tumor of any size with direct extension to the chest wall and/or skin (ulceration or skin nodules) or inflammatory carcinoma
Fig. 2
a, b Kaplan–Meier curves for relapse-free and overall survival of all cases by regional lymph nodes status (cN-category) N0 no regional lymph node metastases, N1 metastases in movable ipsilateral level I, II axillary lymph node(s), N2 metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted OR Metastases in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases, N3 metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involvement OR Metastases in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases OR Metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. P values were calculated using the log rank test
Fig. 3
a, b Kaplan–Meier curves for relapse-free and overall survival of all cases by clinical stage (UICC). P values were calculated using the log rank test
Fig. 4
a, b Kaplan–Meier curves for relapse-free and overall survival of cases without neoadjuvant therapy by pathological tumor size (pT size). Tumor size is a marker of invasiveness. P values were calculated using the log rank test
Fig. 5
a, b Kaplan–Meier curves for relapse-free and overall survival of cases without neoadjuvant therapy by the number of metastatic lymph nodes. P values were calculated using the log rank test
Fig. 6
a, b Kaplan–Meier curves for relapse-free and overall survival of all cases by age. P values were calculated using the log rank test
Fig. 7
a, b Kaplan–Meier curves for relapse-free and overall survival of T1–T4, any N and M0 cases with respect to estrogen receptor (ER) status and HER2 (human epidermal growth factor receptor 2) amplification status. P values were calculated using the log rank test. Relapse-free survival and overall survival of patients with respect to combined ER and HER2 status
Fig. 8
a, b Kaplan–Meier curves for relapse-free and overall survival of ER-positive and M0 cases by progesterone receptor (PgR) status. P values were calculated using the log rank test
Fig. 9
a, b Kaplan–Meier curves for relapse-free and overall survival of ER-positive and M0 cases with respect to PgR and HER2 amplifications. P values were calculated using the log rank test
× ![]()
× ![]()
× ![]()
× ![]()
× ![]()
× ![]()
× ![]()
× ![]()
× ![]()
…